Last reviewed · How we verify
Tetanus — Treatment Landscape & Competitive Intelligence
3 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Valium | diazepam | Generic (originally Roche) | Benzodiazepine [EPC] | Adenosine receptor A3, Aldo-keto reductase family 1 member C1, Aldo-keto reductase family 1 member C2 | 1963-11-15 | |
| Penicillin G Potassium In Plastic Container | Benzylpenicillin | Pfizer | Penicillin-class Antibacterial | 1947-01-01 | ||
| penicillin | penicillin | Karlstad University | Bacterial penicillin-binding protein, Beta-lactamase, Beta-lactamase TEM |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Generic (originally Roche) · 1 drug in Tetanus
- Karlstad University · 1 drug in Tetanus
- Pfizer · 1 drug in Tetanus
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Tetanus:
Cite this brief
Drug Landscape (2026). Tetanus — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/tetanus. Accessed 2026-06-10.
Related
- Tetanus full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing